Arbor Biotechnologies: Unveiled FDA approval of an IND filing for their LNP-mediated treatment for primary hyperoxaluria type 1. Rothwell Figg (Dan Shores): Led a workshop on intellectual property challenges for LNP-based therapies at the LNP Summit. NOF CORPORATION: Presented biodegradable LNPs with tunable immunogenicity for vaccine and gene therapy applications. Serina Therapeutics: Introduced immune-silent POZ-lipid technology as a PEG alternative for LNPs at the

University of Pennsylvania: Developed nitro-oleic acid-modified LNPs for safer plasmid DNA delivery, enabling long-term gene expression in mice. ACS Biochemistry Study: Introduced click chemistry LNPs for targeted mRNA delivery to metabolically labeled cancer cells. Marama Labs: Launched CloudSpec, a tool for rapid lipid nanoparticle analysis, reducing lab times from hours to seconds. Global Market Report: Projected lipid nanoparticle market growth to US$2.39 billion by 20

Sanofi: Published research in Nanoscale on optimizing PEGylated lipids for enhanced mRNA delivery efficacy and stability. University of

Serina Therapeutics: Presented preclinical data on non-immunogenic POZ-lipid technology at the ACS Spring 2025 Meeting. Genevant Sciences an

Frontiers in Nanotechnology: Published research article on RNA-lipid nanoparticle therapeutics for women's health, focusing on gynecological

News Summary Nature: Published research on fabrication of mRNA encapsulated lipid nanoparticles using SMART-MaGIC technologies. Clinical P

Summary of Recent LNP News Johns Hopkins Institute for NanoBioTechnology: Developed a machine learning model to predict efficient lipid nano

Section 1: Brief Summary of News Nature: Published research on improving safety of lipid nanoparticle-based DNA delivery by incorporating

1. Arbutus Biopharma Appoints New CEO and Restructures Board to Prioritize LNP Technology Release Date : February 25, 2025 Source :...